EGFR and non-small cell lung carcinoma: A retrospective study of 306 NSCLC patients compared the efficacy of 1st- and 2nd-generation EGFR TKIs showed no significant differences in the cumulative incidences of subsequent BM at 6, 12, and 24 months when comparing gefitinib vs erlotinib and afatinib (p = 0.80) [33].